Synthesis and Development of Indole Based 5-HT3 Receptor Antagonists as Anti-Emetic Drugs in Oncology :An Update

被引：2

作者：

Rivera-Fonseca, Johana L. ^{[1
,2
]}

Gonzalez-Rivas, Nelly ^{[1
,2
]}

Basavanag Unnamatla, M., V ^{[1
,2
]}

Garcia-Eleno, Marco A. ^{[1
,2
]}

Reyes, Horacio ^{[3
]}

German Lopez-Valdez, L. ^{[4
]}

Corona-Becerril, David ^{[1
,2
]}

Cuevas-Yanez, Erick ^{[1
,2
]}

机构：

[1] UAEM UNAM, Ctr Conjunto Invest Quim Sustentable, Carretera Toluca Atlacomulco Km 14-5, Toluca 50200, Estado De Mexic, Mexico

[2] Univ Autonoma Estado Mexico, Fac Quim, Toluca 50120, Mexico

[3] Tecnol Estudios Super Jocotitlan, Div Ingn Quim, Carretera Toluca Atlacomulco Km 44-8, Jocotitlan, Edo, Mexico

[4] Univ Autonoma Chapingo, Dept Preparatoria Agr, Area Quim, Lab Prod Nat, Apartado 74,Km 38-5 Carretera Mexico Texcoco, Chapingo 56230, Mexico

来源：

CURRENT MEDICINAL CHEMISTRY | 2021年 / 28卷 / 42期

关键词：

Antiemetic drugs; 5-HT3; indole; synthesis; ondansetron; ramosetron; dolasetron; granisetron; ricaset-ron; tropisetron; CHEMOTHERAPY-INDUCED NAUSEA; IRRITABLE-BOWEL-SYNDROME; INDUCED EMESIS; 5-HYDROXYTRYPTAMINE(3) RECEPTORS; PHARMACOLOGICAL PROFILE; POSTOPERATIVE NAUSEA; ANTICIPATORY NAUSEA; THERAPEUTIC AGENT; CHRONIC TOXICITY; VOMITING CINV;

D O I：

10.2174/0929867328666210708091134

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

An important group of antiemetic drugs used in the treatment of nausea and vomiting after chemotherapy containing an indole moiety in their structures, working as 5hydroxytryptamine type 3 serotonin receptor antagonist (5-HT3). This study focuses on compounds bearing an indole core that present a 5-HT3 receptor antagonist activity, which have been successfully used as antiemetic drugs for reducing chemotherapy adverse secondary effects during cancer treatment. Their synthesis, biological activities, and some outstanding characteristics are discussed, providing a general outlook towards the development of more efficient antiemetic drugs.

引用

页码：8733 / 8754

页数：22

共 50 条

[21] 5-HT3 RECEPTOR ANTAGONISTS AND MIGRAINE THERAPY
FERRARI, MD
JOURNAL OF NEUROLOGY, 1991, 238 : S53 - S56
[22] ANXIOLYTIC POTENTIAL OF 5-HT3 RECEPTOR ANTAGONISTS
COSTALL, B
NAYLOR, RJ
PHARMACOLOGY & TOXICOLOGY, 1992, 70 (03): : 157 - 162
[23] Azologization of serotonin 5-HT3 receptor antagonists
Rustler, Karin
Maleeva, Galyna
Bregestovski, Piotr
Koenig, Burkhard
BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, 2019, 15 : 780 - 788
[24] Serotonin 5-HT3 and 5-HT4 receptor antagonists
Gaster, LM
King, FD
MEDICINAL RESEARCH REVIEWS, 1997, 17 (02) : 163 - 214
[25] Oncology nurse survey of 5-HT3 receptor antagonists use in clinical practice.
Baum, B
Rothaermel, J
Shear, J
Ramer, B
DeMeyer, E
ONCOLOGY NURSING FORUM, 2006, 33 (02) : 438 - 438
[26] Additional binding mechanism of palonosetron to the 5-HT3 receptor versus first generation 5-HT3 receptor antagonists
Rojas, C.
Stathis, M.
Alt, J.
Rubenstein, E.
Cantoreggi, S.
Sebastiani, S.
Slusher, B.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[27] MECHANISM OF THE ANTIEMETIC ACTIVITY OF 5-HT3 RECEPTOR ANTAGONISTS
TYERS, MB
FREEMAN, AJ
ONCOLOGY, 1992, 49 (04) : 263 - 268
[28] 5-HT3 RECEPTOR ANTAGONISTS - A NEW CLASS OF ANTIEMETICS
不详
LANCET, 1987, 1 (8548): : 1470 - 1471
[29] EMERGING DIFFERENCES BETWEEN 5-HT3 RECEPTOR ANTAGONISTS
MARR, HE
DAVEY, PT
BARTLETT, AJ
ANTI-CANCER DRUGS, 1991, 2 (06) : 513 - 518
[30] Current experience with 5-HT3 receptor antagonists in fibromyalgia
Späth, M
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2002, 28 (02) : 319 - +

← 1 2 3 4 5 →